Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab

被引:7
|
作者
Yoshida, Shun [1 ]
Hanai, Shunichiro [1 ]
Nakagomi, Daiki [1 ]
Kobayashi, Kei [1 ]
Takahashi, Kazuya [1 ]
Furuya, Fumihiko [1 ]
机构
[1] Univ Yamanashi, Dept Internal Med 3, Kofu, Yamanashi, Japan
关键词
small vessel vasculitis; glomerular disease; secondary membranous nephropathy; immune complex deposits; immunofluorescence staining; CRESCENTIC GLOMERULONEPHRITIS; MYELOPEROXIDASE; DEPOSITS; CYCLOPHOSPHAMIDE;
D O I
10.2169/internalmedicine.4752-20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Membranous nephropathy (MN) with anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN) is seen infrequently. Previous reports of patients with ANCA-GN with MN showed that the most frequent ANCA subtype was myeloperoxidase-ANCA. We herein present a 73-year-old woman with scleritis, hematuria, proteinuria, and positive serum proteinase 3 (PR3)-ANCA. She underwent a renal biopsy and was diagnosed with MN and ANCA-GN. Immunofluorescence staining for PR3 colocalized with IgG along the glomerular basement membrane were observed. Oral prednisolone and intravenous rituximab therapy immediately improved her symptoms and urinalysis abnormalities. PR3-ANCA may be involved in the pathogenesis of MN via the formation of immune complexes.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 50 条
  • [41] Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy
    Qi Xiong
    Wei Lin
    Chanjuan Shen
    Ting Meng
    Rong Tang
    Joshua D. Ooi
    Peter J. Eggenhuizen
    Jinbiao Chen
    Wannian Nie
    Xia Li
    Qiaoling Zhou
    Ping Xiao
    Yong Zhong
    Xiangcheng Xiao
    Immunologic Research, 2023, 71 : 1 - 14
  • [42] Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
    Treppo, Elena
    Binutti, Marco
    Agarinis, Roberto
    De Vita, Salvatore
    Quartuccio, Luca
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [43] Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients
    Wendt, M.
    Gunnarsson, I.
    Bratt, J.
    Bruchfeld, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (02) : 116 - 119
  • [44] Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?
    Besada, Emilio
    Nossent, Johannes C.
    CLINICAL RHEUMATOLOGY, 2013, 32 (11) : 1677 - 1681
  • [45] Circulating ADAM17 Level Reflects Disease Activity in Proteinase-3 ANCA-Associated Vasculitis
    Bertram, Anna
    Lovric, Svjetlana
    Engel, Alissa
    Beese, Michaele
    Wyss, Kristin
    Hertel, Barbara
    Park, Joon-Keun
    Becker, Jan U.
    Kegel, Johanna
    Haller, Hermann
    Haubitz, Marion
    Kirsch, Torsten
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (11): : 2860 - 2870
  • [46] A case of myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis and concurrent membranous nephropathy
    Shimada, Michiko
    Fujita, Takeshi
    Nakamura, Norio
    Narita, Ikuyo
    Shimaya, Yuko
    Murakami, Reiichi
    Yamabe, Hideaki
    Osawa, Hiroshi
    Okumura, Ken
    BMC NEPHROLOGY, 2013, 14
  • [47] Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis
    Rathmann, Jens
    Stamatis, Pavlos
    Jonsson, Goran
    Englund, Martin
    Segelmark, Marten
    Jayne, David
    Mohammad, Aladdin J.
    RHEUMATOLOGY, 2022, 61 (12) : 4817 - 4826
  • [48] Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis
    Stegeman, CA
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (12) : 2077 - 2080
  • [49] Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use
    Durel, Cecile-Audrey
    Thervet, Eric Simon
    Chauveau, Dominique
    Schmidt, Aurelie
    Terrier, Benjamin
    Bataille, Pierre M.
    BMC RHEUMATOLOGY, 2024, 8 (01)
  • [50] Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?
    Ignacio Garcia-Valladares
    Luis R. Espinoza
    Current Rheumatology Reports, 2010, 12 (6) : 395 - 398